Ionis Pharmaceuticals (IONS) On Mixed Trial And FDA News While The Undervalued Narrative Holds

Ionis Pharmaceuticals experienced a mixed set of trial and FDA regulatory outcomes, with its Lp(a)HORIZON Phase 3 trial failing its primary endpoint while securing FDA approval for a rare disease therapy, causing a significant stock price decline despite a strong rare disease platform narrative.

This Wire brief sits within Fusion42's coverage of Biotech.